07:00 , Oct 28, 2013 |  BC Week In Review  |  Company News

Alzheon, Bellus Health deal

Alzheon received exclusive, worldwide rights from Bellus to ALZ-801 (formerly BLU8499 ), which has completed a Phase I trial for Alzheimer's disease. ALZ -801, a small molecular inhibitor of beta amyloid formation, is a prodrug...
08:00 , Nov 19, 2012 |  BC Week In Review  |  Company News

Bellus Health, Asclepios Bioresearch Ltd. deal

In its 3Q12 earnings, Bellus said that it and venture capital firm Asclepios partnered during the quarter to develop Bellus' BLU8499 (formerly NRM8499 ) to treat Alzheimer's disease. Asclepios will fund Phase IIa development of...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Financial News

Genmedica completes venture financing

Genmedica Therapeutics S.L. , Barcelona, Spain   Business: Endocrine/Metabolic   Date completed: 9/25/12   Type: Venture financing   Raised: €12 million ($15.5 million)   Investor: Asclepios Bioresearch  ...
00:57 , Oct 18, 2012 |  BC Extra  |  Financial News

Genmedica raises EUR 12M in B round

Genmedica Therapeutics S.L. (Barcelona, Spain) raised EUR 12 million ($15.5 million) in a series B round from new investor Asclepios Bioresearch. Genmedica is developing dual inhibitors against pathways of oxidative stress and inflammation for a...